US3787565A - Method of producing a diagnostic preparation on the basis of an iron complex labelled with 99m tc - Google Patents
Method of producing a diagnostic preparation on the basis of an iron complex labelled with 99m tc Download PDFInfo
- Publication number
- US3787565A US3787565A US00146543A US3787565DA US3787565A US 3787565 A US3787565 A US 3787565A US 00146543 A US00146543 A US 00146543A US 3787565D A US3787565D A US 3787565DA US 3787565 A US3787565 A US 3787565A
- Authority
- US
- United States
- Prior art keywords
- solution
- producing
- technetium
- iron complex
- basis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Definitions
- the present invention relates to a method of producing a diagnostic preparation on the basis of an iron complex labelled with 99m Tc, with preparation is of importance for various scintigraphic examinations and especially for examinations of the brain and the kidneys.
- Technetium is in great request for use in medicine owing to its short half-life (6 hours) its u-ray energy (140 kev.) and the absence of emission of SI-rays. As a result, the radiation doses administered to the patients may be reduced, whilst the injected activity and hence the statistical accuracy of the counts is increased and the duration of the examination may be reduced.
- radioactive technetium The wide range of application of radioactive technetium is of great importance, because it enables the store of other radioactive elements to be restricted.
- radioactive technetium may simply be obtained at any desired instant by means of an elution process using, for example, the generator system described in French patent specification No. 1,518,130, in the form of sodium pertechnetate in an isotonic saline solution which may be mixed with the carrier required for the respective examination.
- the method according to the invention is characterized in that there is added to powdered ferrous ascorbate a solution of a technetium cmopund, after which if required, the resulting solution is made alkaline to a pH between 7 and 8, and finally the reaction mixture is agitated.
- the powdered ferro-ascorbate may be dissolved in an aqueous medium such, for example, as a physiological saline solution.
- the reaction mixture is agitated in the presence of air, until a violet color appears. This treatment takes a few minutes. The violet color corresponds to the formation of a technetium-labelled ion complex.
- the resulting product is ready for use and may be injected into the patient to be examined.
- the product is stable for several hours.
- the freeze-dried ferrous ascorbate has the further advantage that it remains stable for a prolonged period of time.
- the technetium compound used in the method according 'to the invention preferably is sodium pertechnetate.
- the adjustment of the pH of the reaction mixture preferably is eifected by means of a trihydroxymethylaminomethane solution (sometimes referred to as Tris or THAM) which previously has been buffered to a pH of about 8 by the addition of hydrochloric acid.
- Tris or THAM trihydroxymethylaminomethane solution
- the starting product is a powdered mixture of ferrous ascorbate and a basic substance.
- the amount of basic substance is such that after the solution of the technetium compound has been added the reaction mixture has a pH of from 7 to 8.
- the basic substance preferably has a buffer capacity at pH values between 7 and 8.
- the adjustment of the pH after the addition of the technetium compound is not necessary.
- the method according to the invention eliminates the afore-described disadvantages.
- a further advantage of the method according to the invention consists in an increase in the labelling efliciency.
- the method according to the invention results in a labelling efiiciency of from to 97%.
- the invention also relates to a kit to be marketed as a unit which is suitable for use in the method according to the invention, which kit comprises at least one bottle of sterilized powdered ferrous ascorbate and at least one bottle of sterilized alkaline substance.
- bottles other hermetically sealed containers, such as ampoules, may be used in the kit according to the invention.
- the required radioactive solution must be prepared in situ by means of elution of radioactive technetium generator.
- the invention further relates to a new preparation for use in the method according to the invention, which preparation is characterized in that it comprises a pow- EXAMPLE I
- a pow- EXAMPLE I To 33 mg. of ferrous ascorbate there is added 2 ml. of a solution of TcO Na; to the resulting solution there is added 0.8 ml. of a solution of Tris (0.2 M) and the mixture is agitated in the presence of air, until a violet color is produced.
- the labelling efliciency which has been determined by means of anion resins and by thinlayer chromatography, is 95%.
- a method of producing a diagnostic preparation on the basis of an iron complex labelled with 99m Tc comprising adding to powdered ferrous ascorbate a solution of a technetium compound, adjusting the solution to a pH between 7 and 8 if necessary and agitating the reaction mixture in the presence of air until a violet color is produced.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A METHOD OF PRODUCING A TECHNETIUM LABELLED IRON COMPLEX IN WHICH A SOLUTION OF A TECHNETIUM COMPOUND IS REACTED WITH FERROUS ASCORBATE, THE RESULTANT SOLUTION IS MADE ALKALINE AND THE SOLUTION IS THEN AGITATED IN THE PRESENCE OF AIR UNTIL A VIOLET COLOR APPEARS.
Description
United States Patent METHOD OF PRODUCING A DIAGNOSTIC PREPA- RATION ON THE BASIS OF AN IRON COMPLEX LABELLED WITH 99m Tc Jean-Paul Nouel, Boisguillaume, and- Henry Emile Edouard Renault, Paris, France, assignors to US. Philips Corporation, New York, N.Y.
No Drawing. Filed May 24, 1971, Ser. No. 146,543
Claims priority, applifistiopglgrance, May 22, 1970,
Int. Cl. A61k 27/04 US. Cl. 424-1 4 Claims ABSTRACT OF THE DISCLOSURE A method of producing a technetium labelled iron complex in which a solution of a technetium compound is reacted with ferrous ascorbate, the resultant solution is made alkaline and the solution is then agitated in the presence of air until a violet color appears.
The present invention relates to a method of producing a diagnostic preparation on the basis of an iron complex labelled with 99m Tc, with preparation is of importance for various scintigraphic examinations and especially for examinations of the brain and the kidneys.
Technetium is in great request for use in medicine owing to its short half-life (6 hours) its u-ray energy (140 kev.) and the absence of emission of SI-rays. As a result, the radiation doses administered to the patients may be reduced, whilst the injected activity and hence the statistical accuracy of the counts is increased and the duration of the examination may be reduced.
Furthermore technetium is frequently used for various examinations (thyroid, brain, liver, kidneys, spleen) in combination with various carriers.
The wide range of application of radioactive technetium is of great importance, because it enables the store of other radioactive elements to be restricted.
In addition, the radioactive technetium may simply be obtained at any desired instant by means of an elution process using, for example, the generator system described in French patent specification No. 1,518,130, in the form of sodium pertechnetate in an isotonic saline solution which may be mixed with the carrier required for the respective examination.
The use of a preparation on the basis of a technetiumlabelled iron complex for various scintigraphic analyses, in particular of the brain and the kidneys, is known and has often been described in the literature. According to a method of production described in Am. J. Rontg. (101), 1967, pp. 152-156, a pertechnetate solution is added to a solution of ascorbic acid and ferric chloride, after which the pH is first adjusted to 1.5 and then to about 7.4. Since the labelling efficiency is comparatively small, the technetium which has not been bound to the resulting complex is removed by means of an anion resin. The actual preparation is very difficult and requires a large number of operations, which consume much time and give rise to sterility problems. Especially the sterility problems are troublesome. All the operations, such as producing the solution of ascorbic acid, the solution of ferric chloride, adding the pertechnetate solution to the solution of ascorbic acid and ferric chloride, adjusting the pH to 1.5 and then to 7.4 and removing the unbound technetium, must be performed under strictly sterile conditions. This often cannot be realized, so that the ultimate product must again be sterilized.
These objections also apply to a method described in Medical Radio Isotope Scintigraphy Symposium, Salzburg, August 1968, vol. II, p. 627, in which ferrous sulphate is used instead of ferric chloride, although in this method the necessary operations are simplified to some extent.
We have now found a new method of producing a 99m Tc-labelled iron complex which does not suft'ffer from the above disadvantages.
The method according to the invention is characterized in that there is added to powdered ferrous ascorbate a solution of a technetium cmopund, after which if required, the resulting solution is made alkaline to a pH between 7 and 8, and finally the reaction mixture is agitated. Immediately before use the powdered ferro-ascorbate may be dissolved in an aqueous medium such, for example, as a physiological saline solution.
The reaction mixture is agitated in the presence of air, until a violet color appears. This treatment takes a few minutes. The violet color corresponds to the formation of a technetium-labelled ion complex.
The resulting product is ready for use and may be injected into the patient to be examined. The product is stable for several hours.
More particularly, it has been found that satisfactory results are obtained by using freeze-dried ferrous ascorbate in the method according to the invention.
The freeze-dried ferrous ascorbate has the further advantage that it remains stable for a prolonged period of time.
The technetium compound used in the method according 'to the invention preferably is sodium pertechnetate. The adjustment of the pH of the reaction mixture preferably is eifected by means of a trihydroxymethylaminomethane solution (sometimes referred to as Tris or THAM) which previously has been buffered to a pH of about 8 by the addition of hydrochloric acid.
In a preferred embodiment of the method according to the invention, the starting product is a powdered mixture of ferrous ascorbate and a basic substance. The amount of basic substance is such that after the solution of the technetium compound has been added the reaction mixture has a pH of from 7 to 8. The basic substance preferably has a buffer capacity at pH values between 7 and 8.
In this preferred embodiment of the method according to the invention, the adjustment of the pH after the addition of the technetium compound is not necessary.
As has been mentioned hereinbefore, the method according to the invention eliminates the afore-described disadvantages. A further advantage of the method according to the invention consists in an increase in the labelling efliciency. The method according to the invention results in a labelling efiiciency of from to 97%.
The invention also relates to a kit to be marketed as a unit which is suitable for use in the method according to the invention, which kit comprises at least one bottle of sterilized powdered ferrous ascorbate and at least one bottle of sterilized alkaline substance.
Obviously instead of bottles other hermetically sealed containers, such as ampoules, may be used in the kit according to the invention.
It should be mentioned that the solution of a radioactive technetium compound required in the method according to the invention cannot be supplied as such to the user owing to the radioactive disintegration of 99m Tc and hence this solution is not included in the kit according to the invention.
The required radioactive solution must be prepared in situ by means of elution of radioactive technetium generator.
The invention further relates to a new preparation for use in the method according to the invention, which preparation is characterized in that it comprises a pow- EXAMPLE I To 33 mg. of ferrous ascorbate there is added 2 ml. of a solution of TcO Na; to the resulting solution there is added 0.8 ml. of a solution of Tris (0.2 M) and the mixture is agitated in the presence of air, until a violet color is produced. The labelling efliciency, which has been determined by means of anion resins and by thinlayer chromatography, is 95%.
EXAMPLE II To 40 mg. of ferrous ascorbate there is added 5 ml. of a TcO Na solution in 1 ml. of a solution of Tris (1.5 M) buttered to a pH of 8 by means of hydrochloric acid.
The solution is agitated in air until a violet color is produced. The efliciency is about 95 What we claims is: Y
1. A method of producing a diagnostic preparation on the basis of an iron complex labelled with 99m Tc, said method comprising adding to powdered ferrous ascorbate a solution of a technetium compound, adjusting the solution to a pH between 7 and 8 if necessary and agitating the reaction mixture in the presence of air until a violet color is produced.
2. A method as claimed in claim 1, wherein freezedried ferrous ascorbate is used as the starting material.
3. A method as claimed in claim 1, wherein the solution is rendered alkaline by means of trihydroxymethylaminomethane which is buffered to a pH of about 8 by the addition of hydrochloric acid.
4. A method as claimed in claim 1, wherein a powdered mixture of ferrous ascorbate and an alkaline substance is used as the starting material.
References Cited UNITED STATES PATENTS 3,466,361 9/1969 Richards 424-1 BENJAMIN R. PADGE'IT, Primary Examiner UJS. Cl. X.R.
23-230 B; 250l06 T; 252301.1 R
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR7018792A FR2088149B1 (en) | 1970-05-22 | 1970-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3787565A true US3787565A (en) | 1974-01-22 |
Family
ID=9055977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US00146543A Expired - Lifetime US3787565A (en) | 1970-05-22 | 1971-05-24 | Method of producing a diagnostic preparation on the basis of an iron complex labelled with 99m tc |
Country Status (10)
Country | Link |
---|---|
US (1) | US3787565A (en) |
BE (1) | BE767503A (en) |
CA (1) | CA945067A (en) |
CH (1) | CH554667A (en) |
DE (1) | DE2124751A1 (en) |
DK (1) | DK128555B (en) |
FR (1) | FR2088149B1 (en) |
GB (1) | GB1320626A (en) |
IT (1) | IT1050136B (en) |
NL (1) | NL7106774A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3983227A (en) * | 1973-05-23 | 1976-09-28 | The Procter & Gamble Company | Dry mixture containing diphosphonates and a stannous salt useful in the preparation of Tc99M containing bone scanning agents |
US4057617A (en) * | 1975-05-15 | 1977-11-08 | Abramovici J | Method of labeling proteins with technetium |
US4364920A (en) * | 1975-04-30 | 1982-12-21 | Medi-Physics, Inc. | Stable diagnostic reagents |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA761944B (en) * | 1975-04-30 | 1977-03-30 | Procter & Gamble | Stable radiographic scanning agents |
DE4333071C1 (en) * | 1993-09-29 | 1995-02-09 | Roland Man Druckmasch | Method and device for controlling the sheet inlet when starting a sheet-processing printing machine |
-
1970
- 1970-05-22 FR FR7018792A patent/FR2088149B1/fr not_active Expired
-
1971
- 1971-05-18 NL NL7106774A patent/NL7106774A/xx not_active Application Discontinuation
- 1971-05-19 GB GB1577171*[A patent/GB1320626A/en not_active Expired
- 1971-05-19 IT IT24779/71A patent/IT1050136B/en active
- 1971-05-19 DK DK244271AA patent/DK128555B/en unknown
- 1971-05-19 DE DE19712124751 patent/DE2124751A1/en active Pending
- 1971-05-19 CH CH738871A patent/CH554667A/en not_active IP Right Cessation
- 1971-05-21 CA CA113,598A patent/CA945067A/en not_active Expired
- 1971-05-21 BE BE767503A patent/BE767503A/en unknown
- 1971-05-24 US US00146543A patent/US3787565A/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3983227A (en) * | 1973-05-23 | 1976-09-28 | The Procter & Gamble Company | Dry mixture containing diphosphonates and a stannous salt useful in the preparation of Tc99M containing bone scanning agents |
US4364920A (en) * | 1975-04-30 | 1982-12-21 | Medi-Physics, Inc. | Stable diagnostic reagents |
US4057617A (en) * | 1975-05-15 | 1977-11-08 | Abramovici J | Method of labeling proteins with technetium |
Also Published As
Publication number | Publication date |
---|---|
FR2088149B1 (en) | 1974-05-24 |
CA945067A (en) | 1974-04-09 |
CH554667A (en) | 1974-10-15 |
FR2088149A1 (en) | 1972-01-07 |
GB1320626A (en) | 1973-06-20 |
BE767503A (en) | 1971-11-22 |
IT1050136B (en) | 1981-03-10 |
DE2124751A1 (en) | 1971-12-02 |
DK128555B (en) | 1974-05-27 |
NL7106774A (en) | 1971-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zalutsky et al. | Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate | |
JP4649044B2 (en) | Method for producing radium-223 and kit containing radium-223 | |
US5219556A (en) | Stabilized therapeutic radiopharmaceutical complexes | |
US3803299A (en) | Method of producing a diagnostic preparation on the basis of macro-aggregates of serum albumin labelled with | |
Hnatowich et al. | Dysprosium-165 ferric hydroxide macroaggregates for radiation synovectomy | |
US3872226A (en) | Tc{14 99m albumin aggregates with stannous tin and denatured albumin | |
US3961038A (en) | Process for the manufacture of injectable preparations of Tc99m and/or In113m and apparatus for carrying out the process | |
US5853695A (en) | Method for palliation of pain in human bone cancer using therapeutic tin-117m compositions | |
US3466361A (en) | Technetium-99m labeled chelates | |
US4264468A (en) | Generator for gallium-68 and compositions obtained therefrom | |
US3787565A (en) | Method of producing a diagnostic preparation on the basis of an iron complex labelled with 99m tc | |
US3931396A (en) | Method of preparation of a composition having a base of 99m technetium for diagnosis by scintigraphy | |
US4990787A (en) | Radionuclide generator system and method for its preparation and use | |
US3740418A (en) | Radioactive scanning preparation | |
US3928552A (en) | Hepato-biliary radiopharmaceutical comprising 2-mercaptoisobutyric acid chelating reduced technetium-99m | |
Meschan et al. | The utilization of radioactive zinc and manganese in an effort to visualize the pancreas | |
UA125583C2 (en) | Isotope preparation method | |
US4288424A (en) | Generator for ionic gallium-68 based on column chromatography | |
US3812264A (en) | Method of producing a carrier for a scintigraphic preparation and scintigraphic preparations including said carrier | |
Goethals et al. | Cyclotron production of carrier-free 66 Ga as a positron emitting label of albumin colloids for clinical use | |
EP0176288B1 (en) | Aminocarboxylic acid complexes for the treatment of calcific tumors | |
US4066742A (en) | Tc-99m sulfur colloid radiopharmaceuticals | |
Hill et al. | A simplified method for the preparation of indium-DTPA brain scanning agent | |
IE44077B1 (en) | Technetium-99m-labelled diagnostic agent for kidney scanning and process for its manufacture | |
US3749913A (en) | Renal scanning composition and method using technetium 99m |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MAALLINCKRODT DIAGNOSTICA (HOLLAND) B.V., WESTERDU Free format text: CHANGE OF NAME;ASSIGNOR:BYK-MALLINCKRODT CIL B.V.;REEL/FRAME:004466/0151 Effective date: 19850728 |